Immunity to TB in highly immunosuppressed HIV-infected and uninfected individuals
Immunity to TB in highly immunosuppressed HIV-infected and uninfected individuals
批准号:
9205082
负责人:
ANNE GOLDFELD
金额:
$26.97万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-06-24 至 2018-05-31
关键词:
Acquired Immunodeficiency SyndromeAddressAffectAftercareAgingAnti-Retroviral AgentsAntitubercular AgentsArchivesBiological MarkersBlood CellsCCR6 geneCD28 geneCD4 Positive T LymphocytesCD8B1 geneCDKN2A geneCXCR3 geneCambodiaCambodianCause of DeathCell CountCellsCessation of lifeClinicalDNA MethylationDataDifferentiation AntigensDiseaseEnvironmentEpigenetic ProcessExhibitsFrequenciesFutureGrowthHIVImmuneImmune responseImmune systemImmunityImmunocompromised HostImmunophenotypingImmunosuppressionIndividualInfectionInflammatoryInterventionLeadLifeLung diseasesMeasuresMediatingMediator of activation proteinMemoryMycobacterium tuberculosisMycobacterium tuberculosis antigensPatientsPhenotypePremature aging syndromeProliferatingPulmonary TuberculosisRandomized Clinical TrialsRecruitment ActivitySELL geneSamplingSerumSubgroupSyndromeT cell differentiationT cell responseT memory cellT-LymphocyteT-Lymphocyte SubsetsTestingTimeTranscriptTuberculosisadaptive immunityagedantiretroviral therapyarmbaseclinical biomarkersco-infectioncohortcytokinedesignexperienceimmunosuppressedinsightmemory CD4 T lymphocytemethylomemortalitynovel therapeutic interventionnovel therapeuticspatient subsetsperipheral bloodphenotypic biomarkerprematureprophylacticreconstitutionresearch studyresponsesenescenceterminally differentiated effector memory (TEM) T cellstrendtuberculosis immunitytuberculosis treatment
中文摘要
虽然结核分枝杆菌感染是肺部疾病和死亡的最大原因
在全球艾滋病患者中,关于结核病合并感染如何影响长期抗逆转录病毒(ART)的研究知之甚少,
介导的免疫重建。柬埔寨抗逆转录病毒药物的早期与晚期引入(CAMELIA)
随机临床试验显示,在结核病治疗开始后2周早期开始抗逆转录病毒治疗与晚期抗逆转录病毒治疗相比,
在严重免疫功能低下的TB+/HIV+患者中(中位CD 4 =24/mm 3),
导致死亡率显著降低(34%),这一生存益处持续至少3年,
时间干预。在CAMELIA试验的一项科学子研究中,我们发现,
在这些高度免疫抑制的TB+/HIV+患者中,活动性TB疾病导致ART前
几种促炎细胞因子的水平和更高的ART前活化的CD 4+和CD 8 + T细胞频率
细胞,以及显著降低ART前CD 28 + CD 8+和ICOS+ CD 4 + T细胞的频率,
结核病-/艾滋病毒+患者。此外,T细胞亚群频率的这些差异持续至少8个月,
治疗开始后和TB治愈后2个月。此外,我们已经证明,结核病相关的
免疫重建综合征(TB-IRIS),在早期CAMELIA中发生率高2.6倍
治疗组中,导致T细胞区室的深刻变化。例如,TB-IRIS患者
显示出(CD 62 L-CD 45 RA-)效应记忆CD 4 +T细胞的显著ART后扩增和(CD 62 L-CD 45 RA-)效应记忆CD 4 +T细胞的减少。
在(CD 62 L + CD 45 RA-)中枢记忆性CD 4 +T细胞中,与非TB-IRIS患者相比。我们还发现
Th 1样CD 4 + T细胞亚群是CXCR 3 + CCR 6+,被认为介导了大部分抗TB
在TB-IRIS患者中,ART前的反应频率显著升高,
这些细胞在治疗开始后至少8个月保持升高。根据初步数据,我们
假设结核病合并感染加剧了艾滋病毒诱导的免疫系统过早老化,导致
长期后果和不良的回忆反应。在目标1中,我们将研究免疫衰老,
来自TB+/HIV+ CAMELIA和TB-/HIV+和TB+的治疗前存档样本中的甲基化组特征
/艾滋病毒-患者,以及在结核病治疗和抗逆转录病毒治疗后>5年的同一患者的新鲜分离样本中
入会仪式我们进一步假设,在TB+/HIV+组中,经历TB-的患者亚组
IRIS具有上级抗MTb免疫力,一旦开始ART,该免疫力被放大。在目标2中,
比较TB-IRIS与非TB-IRIS患者中的CXCR 3 + CCR 6 + CD 4 + T细胞,以确定其抗MTb
功能这些实验的结果将为HIV+患者中的结核合并感染如何提供重要的见解
在ART介导的免疫之前和之后影响免疫系统的表型和表观遗传特征
重建,他们将阐明TB-IRIS对功能性MTb特异性T细胞的长期影响。
与成功的ART介导的免疫重建和TB治愈相关的反应。
英文摘要
Although infection with Mycobacterium tuberculosis (MTb) is the largest cause of pulmonary disease and death
in HIV patients globally, little is known about how TB co-infection impacts long-term antiretroviral (ART)-
mediated immune reconstitution. The Cambodian Early vs. Late Introduction of Antiretrovirals (CAMELIA)
randomized clinical trial showed that early initiation of ART at 2 weeks after TB therapy initiation versus late
initiation of ART at 8 weeks in severely immunocompromised TB+/HIV+ patients (median CD4=24/mm3),
resulted in a significant (34%) decrease in mortality—a survival benefit that persisted for at least 3 years after
the timing intervention. In a scientific sub-study nested within the CAMELIA trial, we have discovered that
active TB disease in these highly immunosuppressed TB+/HIV+ patients led to significantly greater pre-ART
levels of several pro-inflammatory cytokines and greater pre-ART frequencies of activated CD4+ and CD8+ T
cells, and significantly lower pre-ART frequencies of CD28+CD8+ and ICOS+CD4+ T cells, as compared to
TB-/HIV+ patients. Moreover, these differences in T cell subset frequencies persisted for at least 8 months
after treatment initiation and 2 months after TB cure. Furthermore, we have demonstrated that TB-associated
immune reconstitution syndrome (TB-IRIS), which occurred 2.6-fold more frequently in the early CAMELIA
treatment arm, results in profound changes in the T cell compartment. For example, TB-IRIS patients
exhibited a significant post-ART expansion of (CD62L-CD45RA-) effector memory CD4+T cells and a decrease
in (CD62L+CD45RA-) central memory CD4+T cells as compared to non-TB-IRIS patients. We have also found
that a Th1-like CD4+ T cell subset that is CXCR3+CCR6+ and thought to mediate a large portion of anti-TB
responses was present at significantly elevated frequencies pre-ART in TB-IRIS patients, and the frequency of
these cells remained elevated for at least 8 months after treatment onset. Based on our preliminary data, we
hypothesize that TB co-infection exacerbates HIV-induced premature aging of the immune system, leading to
long-term consequences and poor recall responses. In Aim 1 we will investigate immunosenescent and
methylomic signatures in pre-treatment archived samples from TB+/HIV+ CAMELIA and TB-/HIV+ and TB+
/HIV- patients, and in freshly isolated samples from the same patients >5 years after TB treatment and ART
initiation. We further hypothesize that within the TB+/HIV+ group the subset of patients who experienced TB-
IRIS possessed superior anti-MTb immunity, which was amplified once ART was initiated. In Aim 2 we will
compare CXCR3+CCR6+CD4+ T cells in TB-IRIS versus non-TB-IRIS patients to determine their anti-MTb
function. Findings from these experiments will provide critical insights into how TB co-infection in HIV+ patients
affects phenotypic and epigenetic features of the immune system prior to and following ART-mediated immune
reconstitution, and they will elucidate the long-term consequences of TB-IRIS on functional MTb-specific T cell
responses that were associated with successful ART-mediated immune reconstitution and TB cure.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Discovery of novel regulatory territories in the TNF/LT locus
-
批准号:10650771
-
项目类别:
-
资助金额:$44.25万
-
财政年份:2022
-
负责人:ANNE GOLDFELD
-
依托单位:
Discovery of novel regulatory territories in the TNF/LT locus
-
批准号:10408494
-
项目类别:
-
资助金额:$44.25万
-
财政年份:2022
-
负责人:ANNE GOLDFELD
-
依托单位:
Innate Immune Control of TB and HIV
-
批准号:10426882
-
项目类别:
-
资助金额:$64.61万
-
财政年份:2021
-
负责人:ANNE GOLDFELD
-
依托单位:
Immunity to TB in highly immunosuppressed HIV-infected and uninfected individuals
-
批准号:9303303
-
项目类别:
-
资助金额:$21.84万
-
财政年份:2016
-
负责人:ANNE GOLDFELD
-
依托单位:
Immune control mechanisms of TB latency in the setting of HIV co-infection
-
批准号:9229528
-
项目类别:
-
资助金额:$44.25万
-
财政年份:2016
-
负责人:ANNE GOLDFELD
-
依托单位:
Immune control mechanisms of TB latency in the setting of HIV co-infection
-
批准号:9115843
-
项目类别:
-
资助金额:$44.25万
-
财政年份:2016
-
负责人:ANNE GOLDFELD
-
依托单位:
Host factors, inflammation, and HIV associated TB
-
批准号:9114703
-
项目类别:
-
资助金额:$81.29万
-
财政年份:2015
-
负责人:ANNE GOLDFELD
-
依托单位:
Immune control mechanisms of TB latency in the setting of HIV co-infection
-
批准号:9028020
-
项目类别:
-
资助金额:$44.13万
-
财政年份:2015
-
负责人:ANNE GOLDFELD
-
依托单位:
T CELL SUBSETS AND THEIR FUNCTION IN TB/HIV PARADOXICAL REACTIONS
-
批准号:7753855
-
项目类别:
-
资助金额:$20.79万
-
财政年份:2009
-
负责人:ANNE GOLDFELD
-
依托单位:
T CELL SUBSETS AND THEIR FUNCTION IN TB/HIV PARADOXICAL REACTIONS
-
批准号:7554709
-
项目类别:
-
资助金额:$36.75万
-
财政年份:2009
-
负责人:ANNE GOLDFELD
-
依托单位:
Checkpoints of TNF Gene Regulation
-
批准号:8574081
-
项目类别:
-
资助金额:$22.8万
-
财政年份:2006
-
负责人:ANNE GOLDFELD
-
依托单位:
Checkpoints of TNF Gene Regulation
-
批准号:8850936
-
项目类别:
-
资助金额:$0.73万
-
财政年份:2006
-
负责人:ANNE GOLDFELD
-
依托单位:
Checkpoints of TNF Gene Regulation
-
批准号:7227536
-
项目类别:
-
资助金额:$34.02万
-
财政年份:2006
-
负责人:ANNE GOLDFELD
-
依托单位:
Checkpoints of TNF Gene Regulation
-
批准号:7028018
-
项目类别:
-
资助金额:$35.04万
-
财政年份:2006
-
负责人:ANNE GOLDFELD
-
依托单位:
Checkpoints of TNF Gene Regulation
-
批准号:8187280
-
项目类别:
-
资助金额:$41.4万
-
财政年份:2006
-
负责人:ANNE GOLDFELD
-
依托单位:
Checkpoints of TNF Gene Regulation
-
批准号:9049987
-
项目类别:
-
资助金额:$44.17万
-
财政年份:2006
-
负责人:ANNE GOLDFELD
-
依托单位:
Checkpoints of TNF Gene Regulation
-
批准号:9109364
-
项目类别:
-
资助金额:$42.48万
-
财政年份:2006
-
负责人:ANNE GOLDFELD
-
依托单位:
Checkpoints of TNF Gene Regulation
-
批准号:8474780
-
项目类别:
-
资助金额:$35.81万
-
财政年份:2006
-
负责人:ANNE GOLDFELD
-
依托单位:
Checkpoints of TNF Gene Regulation
-
批准号:8310153
-
项目类别:
-
资助金额:$16.08万
-
财政年份:2006
-
负责人:ANNE GOLDFELD
-
依托单位:
Checkpoints of TNF Gene Regulation
-
批准号:7409689
-
项目类别:
-
资助金额:$34.02万
-
财政年份:2006
-
负责人:ANNE GOLDFELD
-
依托单位:
海外基金